Given the existing preclinical data demonstrating that pretreatment with NHE1 inhibitors or short-term use after hypotension can reduce cardiac dysfunction, clinical studies on patients with cardiac hypertrophy or heart failure need to confirm the optimal timing of drug administration. Here, SLC9A1 is linked to cardiac hypertrophy.